Investigation of Cicaglocal for Wound Healing After Mohs Surgery
Study Overview
This study examines the effectiveness and safety of Cicaglocal, a supplement, in improving wound healing after Mohs surgery for skin cancer. Mohs surgery is a highly effective treatment, but managing wounds can be difficult, especially for older patients.
Methodology
The trial took place at Al-Zahra Hospital in 2023 and involved 24 patients aged 50-80 with skin cancer. Patients were divided into two groups: one received Cicaglocal, and the other received a placebo. The treatments were given after surgery, and various outcomes were assessed 7 and 14 days later, including:
- Reduction of redness (erythema)
- Early healing score (EHS)
- Full recovery
- Patient and physician satisfaction
Results
Cicaglocal showed significantly better results compared to the placebo in all measured outcomes, indicating it can effectively enhance wound healing.
Conclusion
Cicaglocal improves wound healing and overall clinical results after Mohs surgery.
Clinical Trial Importance
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, helps integrate clinical standards and research into a user-friendly resource for healthcare providers.
Practical Solutions
In today’s healthcare setting, efficiency is vital. Our mobile apps assist with:
- Scheduling appointments
- Monitoring treatments
- Telemedicine services
This makes it easier to manage patient care and expand services digitally.
Enhancing Patient Care
By implementing AI, clinics can streamline their operations, improve patient outcomes, and reduce paperwork. Discover more at aidevmd.com.
